Quantum Cyber NV(QUCY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 5:20 PM ET (Korea 11/7 07:20)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 69.87% | Shs Outstand | 87.2M | Perf Week | -14.99% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 26.3M | Perf Month | -48.63% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.08 | Inst Own | 0.27% | Short Float | 4.75% | Perf Quarter | -48.63% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | -12.38% | Short Ratio | 2.04 | Perf Half Y | 96.51% |
| Sales | - | P/B | 0.88 | EPS next 5Y | 79.59% | ROA | - | Short Interest | 1.25M | Perf YTD | -36.24% |
| Book/sh | 0.81 | P/C | 4.66 | EPS past 3/5Y | 66.9% 8.38% | ROE | - | 52W High | -85.52% ($4.93) | Perf Year | -47.49% |
| Cash/sh | 0.15 | P/FCF | - | Sales past 3/5Y | 0.45% 1.7% | ROIC | - | 52W Low | 138.03% ($0.30) | Perf 3Y | -99.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.95% | Gross Margin | - | Volatility(W/M) | 11.4% 10.81% | Perf 5Y | -99.82% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.56 | EPS Q/Q | 97.59% | Profit Margin | - | RSI (14) | 29.71 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.56 | Sales Q/Q | -100% | SMA20 | -23.31% ($0.93) | Beta | 2.45 | Target Price | $9 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/04/14 | SMA50 | -40.58% ($1.19) | Rel Volume | 0.33 | Prev Close | $0.7 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - -58.95% | SMA200 | -40.44% ($1.19) | Avg Volume(3M) | 0.61M | Price | $0.71 |
| IPO | 2021/11/5 | Option/Short | No/Yes | Trades | 363 | Volume | 202,357 | Change | 2.41% |
🧬 This European biotech develops and sells molecular genetics-based early cancer diagnostic test kits. It is best known for ColoAlert, a stool-based colorectal cancer test, and in 2025, along with a company name change, its ticker changed from MYNZ to . It has recently been shifting its business focus toward early pancreatic cancer diagnostics.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded less than usual. That is 33% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +79.6% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
It ranks #37 of 44 in the industry
Based on market cap of $62M.
FAQ
What kind of company is QUCY?
QUCY belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of QUCY?
The market cap of QUCY is approximately $62M, ranking 4,723 within its sector.
What is the 52-week high and low for QUCY?
QUCY has recorded a 52-week high of $4.93 and a low of $0.30.
